NCT07097363
- Conditions
- B-Cell Non-Hodgkin Lymphoma, Burkitt Lymphoma, DNA Virus Infections, +23 more
- Locations
-
- Fred Hutch/University of Washington Cancer Consortium Seattle, Washington, United States
Clinical trial condition
EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
Explore clinical trials studying EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified. Study availability and eligibility vary by location and protocol.
6 public trials
2 recruiting studies
EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified trial results
NCT04231877
- Conditions
- ALK-Positive Large B-Cell Lymphoma, Aggressive Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, +17 more
- Locations
-
- Fred Hutch/University of Washington Cancer Consortium Seattle, Washington, United States
Active, Not Recruiting
Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas
NCT03984448
- Conditions
- Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Diffuse Large B-cell Lymphoma, Double-Expressor Lymphoma, +16 more
- Locations
-
- University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States
- Anchorage Associates in Radiation Medicine Anchorage, Alaska, United States
- Anchorage Radiation Therapy Center Anchorage, Alaska, United States
- Alaska Breast Care and Surgery LLC Anchorage, Alaska, United States
Active, Not Recruiting
Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma
NCT04799275
- Conditions
- Ann Arbor Stage III Diffuse Large B-Cell Lymphoma, Ann Arbor Stage IIX (Bulky) Diffuse Large B-Cell Lymphoma, Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma, +30 more
- Locations
-
- Banner University Medical Center - Tucson Tucson, Arizona, United States
- University of Arizona Cancer Center-North Campus Tucson, Arizona, United States
- University of Arkansas for Medical Sciences Little Rock, Arkansas, United States
- Kaiser Permanente-Anaheim Anaheim, California, United States
Active, Not Recruiting
Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas
NCT03038672
- Conditions
- ALK-Positive Large B-Cell Lymphoma, Burkitt Lymphoma, DNA Virus Infections, +53 more
- Locations
-
- Mayo Clinic Hospital in Arizona Phoenix, Arizona, United States
- Mayo Clinic in Arizona Scottsdale, Arizona, United States
- Mayo Clinic in Florida Jacksonville, Florida, United States
- Moffitt Cancer Center-International Plaza Tampa, Florida, United States
Active, Not Recruiting
Zanubrutinib and CAR T-cell Therapy for the Treatment of Recurrent or Refractory Aggressive B-cell Non-Hodgkin's Lymphoma or Transformed Indolent B-cell Lymphoma
NCT05202782
- Conditions
- Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation, EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Hemic and Lymphatic Diseases, +27 more
- Locations
-
- Northwestern University Chicago, Illinois, United States
- Medical College of Wisconsin Milwaukee, Wisconsin, United States